FOXO4-DRI: Complete Research Guide & Chemical Profile

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a modified peptide designed to selectively induce apoptosis in senescent cells by disrupting the protein-protein interaction between the forkhead box O4 (FOXO4) transcription factor and the tumor suppressor protein p53. The peptide consists of D-amino acids assembled in reverse sequence order compared to the native FOXO4 segment that interfaces with p53, a design strategy known as D-retro-inverso (DRI) modification. This approach preserves the spatial orientation of amino acid side chains while conferring substantial resistance to proteolytic degradation.

• Name: FOXO4-DRI (FOXO4-D-Retro-Inverso)
• Target: FOXO4-p53 protein-protein interaction
• Design: D-retro-inverso modification of FOXO4 CR3 domain segment
• Amino Acid Composition: All D-amino acids in reversed sequence
• Approximate Length: ~30-49 amino acid residues (varies by construct)
• Classification: Senolytic peptide, protein-protein interaction inhibitor
• Mechanism: Competitive disruption of FOXO4-p53 nuclear foci
• CAS Registry: Not yet assigned (research compound)

The D-retro-inverso (DRI) approach is a peptide engineering strategy in which the chirality of each amino acid is inverted from L to D while simultaneously reversing the sequence order. This dual modification results in a peptide whose side chain topology approximately mirrors that of the parent L-peptide, preserving the ability to interact with the same binding partners. The amide bond directionality is reversed, but the overall spatial presentation of functional groups is maintained.

For FOXO4-DRI, this strategy targets the CR3 (C-terminal regulatory region 3) domain of FOXO4, which mediates direct binding to the DNA-binding domain of p53. Biophysical investigation by Kim et al. (2022) demonstrated that the FOXO4 FHD-p53 TAD and FOXO4 CR3-p53 DBD interactions both have micromolar binding affinities, with the CR3-DBD interaction representing a druggable interface. The DRI modification confers proteolytic resistance exceeding that of the native L-peptide by orders of magnitude, enabling sustained biological activity in cell culture and in vivo models.

In senescent cells, FOXO4 and p53 co-localize in nuclear foci known as promyelocytic leukemia (PML) bodies, where their interaction maintains a state of viable cell cycle arrest rather than apoptosis. By sequestering p53 within these nuclear foci, FOXO4 prevents p53 from activating its pro-apoptotic transcriptional program at mitochondria and other cytoplasmic targets. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, displacing p53 from nuclear foci and enabling its translocation to the cytoplasm where it triggers intrinsic apoptosis.

This mechanism is inherently selective for senescent cells because the FOXO4-p53 interaction is upregulated specifically in the senescent state. Non-senescent cells do not rely on FOXO4 to restrain p53, so FOXO4-DRI exposure does not trigger apoptosis in proliferating or quiescent cells. Kong et al. (2025) demonstrated that FOXO4-DRI promotes p53-serine15 phosphorylation nuclear exclusion in keloid senescent fibroblasts, accompanied by increased apoptosis and decreased G0/G1 phase cell populations.

Cellular senescence is a state of stable cell cycle arrest accompanied by a characteristic secretory phenotype known as the senescence-associated secretory phenotype (SASP). Senescent cells accumulate in tissues with aging and secrete pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases that can promote tissue dysfunction, chronic inflammation, and age-related pathology.

Senolytics are a class of compounds that selectively eliminate senescent cells by exploiting their anti-apoptotic dependencies. While senescent cells resist apoptosis through multiple pro-survival pathways (BCL-2 family, PI3K/AKT, p21, and FOXO4-p53), targeting these vulnerabilities can tip senescent cells into apoptosis without affecting normal cells. FOXO4-DRI specifically targets the FOXO4-p53 pro-survival axis, distinguishing it mechanistically from BCL-2 family inhibitors and kinase-based senolytics.

FOXO4-DRI has been investigated in multiple preclinical research contexts related to aging biology and senescence-associated pathology. Research applications span from fundamental studies of senescent cell biology to translational models of age-related diseases.

• Aging biology: clearance of senescent cells in aged mouse models, restoration of tissue homeostasis, investigation of senescence burden on organ function
• Cancer research: targeting senescent cancer-associated fibroblasts (CAFs) to overcome radioresistance in non-small cell lung cancer (Meng et al., 2021)
• Fibrosis: reduction of radiation-induced pulmonary fibrosis through elimination of senescence-like fibroblasts in vivo
• Keloid research: induction of apoptosis in senescent keloid fibroblasts, potential anti-scarring applications (Kong et al., 2025)
• Senolytic drug development: molecular modelling of FOXO4-p53 interface for rational design of improved senolytic peptides (Le et al., 2021)

The D-retro-inverso modification confers exceptional proteolytic stability to FOXO4-DRI compared to conventional L-peptides. D-amino acid peptides are resistant to the vast majority of endogenous proteases and peptidases, which are stereospecific for L-configured substrates. This resistance translates to extended biological half-life both in cell culture media and in vivo.

• Proteolytic stability: high resistance to serum proteases, trypsin, chymotrypsin, and other endopeptidases due to D-amino acid backbone
• Cell penetration: demonstrated ability to cross cell membranes and localize to the nucleus; peptide constructs often include cell-penetrating sequences
• In vivo delivery: typically administered via intraperitoneal or intravenous injection in preclinical models
• Selectivity window: induces apoptosis selectively in senescent cells at concentrations that do not affect proliferating or quiescent cells
• Immunogenicity: D-peptides generally exhibit reduced MHC presentation and lower immunogenic potential than L-peptide counterparts

The senolytic field encompasses multiple mechanistic classes. FOXO4-DRI is unique in targeting the FOXO4-p53 protein-protein interaction, whereas other established senolytics act through different anti-apoptotic pathways. Le et al. (2021) used molecular modelling of the FOXO4-TP53 interaction to design rationally improved senolytic peptides with enhanced potency compared to the original FOXO4-DRI construct.

• FOXO4-DRI: targets FOXO4-p53 interaction; peptide-based; high selectivity for senescent cells; proteolytically stable; requires injection delivery
• Dasatinib + Quercetin (D+Q): tyrosine kinase inhibitor + flavonoid combination; targets multiple pro-survival pathways (PI3K, BCL-2, p21); orally bioavailable
• ABT-263 (Navitoclax): BCL-2/BCL-xL/BCL-w inhibitor; potent senolytic; dose-limited by thrombocytopenia due to platelet BCL-xL dependence
• ABT-737: BCL-2/BCL-xL inhibitor; research tool compound; precursor to navitoclax; limited oral bioavailability
• Fisetin: natural flavonoid; senolytic and senomorphic properties; favorable safety profile; lower potency than pharmacological senolytics

• Lyophilized powder: store at -20°C to -80°C; protect from moisture; stable for 12+ months
• Reconstitution: dissolve in sterile DMSO for stock solution (typically 10-50 mM); dilute in PBS or culture medium for working concentrations
• Working solutions: prepare fresh or store aliquots at -20°C; avoid repeated freeze-thaw cycles
• DMSO stock concentration: maintain below 0.1-0.5% final DMSO in cell culture to avoid solvent toxicity
• In vivo formulation: typically dissolved in vehicle containing DMSO and PEG or cyclodextrin for injection

Quality assessment of FOXO4-DRI requires specialized analytical methods that account for its all-D-amino acid composition. Standard protein analysis methods may yield anomalous results due to the non-canonical chirality.

• RP-HPLC: primary purity assessment; >95% purity expected for research-grade material; D-peptides show characteristic retention time shifts compared to L-counterparts
• Mass spectrometry (MALDI-TOF or ESI-MS): confirms correct molecular weight and sequence identity
• Chiral amino acid analysis: acid hydrolysis followed by chiral chromatography confirms all-D configuration and absence of L-amino acid contamination
• Circular dichroism (CD): D-peptides produce mirror-image CD spectra compared to L-peptides; useful for verifying correct chirality
• Bioactivity assay: senescent cell apoptosis induction (e.g., SA-beta-galactosidase-positive cells) with concurrent non-senescent cell viability confirmation

FOXO4-DRI remains a preclinical research tool that has demonstrated proof-of-concept for senolytic peptide therapy in multiple animal models. Key advancements include the demonstration of senescent fibroblast clearance in vivo, radiosensitization of cancer through senescent CAF elimination, and rational design of improved FOXO4-p53 disrupting peptides through molecular modelling approaches.

Current limitations include the requirement for parenteral delivery (peptides are not orally bioavailable), the cost and complexity of synthesizing long all-D-amino acid peptides at scale, and the need for more comprehensive pharmacokinetic and toxicological characterization. Additionally, the heterogeneity of senescent cell populations means that FOXO4-p53-dependent senescent cells represent only a subset of total senescent cells; combination approaches with mechanistically distinct senolytics may be required for comprehensive senescent cell clearance.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism